The purpose of this study is to determine the safety and effectiveness of rituximab
(anti-CD20) in treating systemic lupus erythematosus (SLE).
White blood cells in the body called B cells give off substances that are active in promoting
SLE disease. Researchers have found that anti-CD20 can block production of these substances
in another disease. This study explores whether anti-CD20 will also be safe in people with
SLE and whether it may be effective in treating SLE.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)